Checkpoint Therapeutics reports developments in oncology drug commercialization, clinical regulation and corporate finance. The company focuses on immunotherapy and targeted oncology treatments for solid tumor cancers, including UNLOXCYT (cosibelimab-ipdl), an FDA-approved anti-PD-L1 antibody for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.
Recurring updates include FDA communications, Biologics License Application activity, commercial preparation for UNLOXCYT, and pipeline disclosures involving cosibelimab and olafertinib, a third-generation EGFR inhibitor for EGFR mutation-positive non-small cell lung cancer. Company news also covers operating results, capital-structure actions, material agreements, governance matters and shareholder voting topics.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.